Abatacept reduced the risk for diabetes in patients with rheumatoid arthritis.
The use of the disease-modifying antirheumatic drug (DMARD) abatacept could lead to a reduction in the risk for diabetes in patients with rheumatoid arthritis (RA), according to a study presented at the 2018 ACR/ARHP Annual Meeting, October 19-24, in Chicago, Illinois.
Researchers in this retrospective study analyzed data from the Truven Marketscan database to group patients with RA by the DMARD they were using for treatment: abatacept, infliximab, adalimumab, golimumab, certolizumab, etanercept, tocilizumab, or tofacitinib.
The researchers followed the participants until they were diagnosed with diabetes or reached the end of the 10-year study. For outcome purposes, they performed an analyses with the entire study group divided into new biologic initiators, which were patients who were biologic treatment naive (n=56,014), or biologic switchers, which were patients who changed biologic treatments (n=27,152).
The study population had an average age of 50 years, was about 75% female, and used infliximab, adalimumab, and etanercept treatments most frequently. Overall, there were 335 new cases of diabetes in the new biologic initiator group and 155 in the biologic switchers group.
|Read on: Abatacept May Reduce Diabetes Risk in Rheumatoid Arthritis|